Polymer Nanoparticle-Based Photodynamic Therapy Combined with Immunotherapy for Solid Tumor Treatment.

Jieling Lao, Qiuting Ye, Shijie Fan, Zhengqing Cheng, Pan Wu

Abstract readReview

In one paragraph

Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jieling LaoState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.

Qiuting YeState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.

Shijie FanState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.

Zhengqing ChengState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.

Pan WuState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.

Funding

the Guangxi Natural Science Foundation 2023GXNSFBA026206the National Natural Science Foundation of China 82360563

6 · The paper itself

Abstract

Polymer nanoparticles have been widely studied for tumor treatment due to their excellent biocompatibility, structural diversity, and multi-functionality. Among their various applications, combining polymer-based photosensitizers with photodynamic therapy (PDT) and immunotherapy has emerged as a promising strategy for treating solid tumors. This combination not only enhances local tumor ablation but also activates systemic antitumor immune responses. Polymer Nanoparticles, with their unique photodynamic properties and ability to integrate multiple therapeutic modalities, offer a powerful platform for photo-immunotherapy. This review systematically discusses recent advances in the design of polymer Nanoparticles and their synergistic mechanisms when combined with immunomodulatory agents such as Toll-like receptor (TLR) agonists, STING agonists, and immune checkpoint inhibitors (ICBs). Moreover, we highlight challenges faced in clinical translation and outline future perspectives for the development of these combination therapies.

Indexed as

immunotherapyphotodynamic therapypolymer nanoparticlestumor treatment

Identifiers

PMID41899433

DOI10.3390/cimb48030281

PMCPMC13025029

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.